TYPHERIX VACCINE 25 mcg/0.5 ml

Country: Сингапур

Језик: Енглески

Извор: HSA (Health Sciences Authority)

Активни састојак:

VI POLYSACCHARIDE OF SALMONELLA TYPHI

Доступно од:

GLAXOSMITHKLINE PTE LTD

АТЦ код:

J07AP03

Дозирање:

25 mcg/0.5 ml

Фармацеутски облик:

INJECTION

Пут администрације:

INTRAMUSCULAR

Тип рецептора:

Prescription Only

Произведен од:

GLAXOSMITHKLINE BIOLOGICALS SA

Датум одобрења:

1999-10-02

Информативни летак

 
TYPHERIX
TM

VI POLYSACCHARIDE TYPHOID VACCINE 

QUALITATIVE AND QUANTITATIVE COMPOSITION 
TYPHERIX
TM
 is a clear isotonic colourless solution containing the cell
surface Vi 
polysaccharide extracted from _Salmonella typhi_ Ty2 strain. 
TYPHERIX
TM
 complies with WHO and European Pharmacopoeia monograph
requirements for 
Vi polysaccharide typhoid vaccines. 
Each 0.5 ml dose of vaccine contains 25 
g of the Vi polysaccharide of _Salmonella typhi_. 

PHARMACEUTICAL FORM

Solution for injection. 

CLINICAL PARTICULARS

INDICATIONS   
Active immunisation against typhoid fever for adults and children
older than two years of 
age. 

DOSAGE AND ADMINISTRATION

POSOLOGY 
A single dose of 0.5 ml containing 25 
g of the Vi polysaccharide of _Salmonella typhi_  is 
recommended for both children and adults. 
Subjects who remain at risk of typhoid fever should be revaccinated
using a single dose of 
vaccine every 3 years. 

METHOD OF ADMINISTRATION 
TYPHERIX
TM
 is for INTRAMUSCULAR injection. 
TYPHERIX
TM
 should be administered with caution to subjects with
thrombocytopenia or 
bleeding disorders since bleeding may occur following an
intramuscular administration to 
these subjects: following injection,  firm pressure should be
applied to the site (without 
rubbing) for at least two minutes. 

CONTRAINDICATIONS 
TYPHERIX
TM
 should not be administered to subjects
with known hypersensitivity to any 
component of the vaccine or to subjects having shown signs of
hypersensitivity after previous 
administration. 

WARNINGS AND PRECAUTIONS 
As with other vaccines, the administration of TYPHERIX
TM
 should be postponed in subjects 
suffering from acute febrile illness. 
The vaccine protects against typhoid fever caused by _Salmonella
typhi_. Protection is not 
conferred against paratyphoid fever or illness caused by
non-invasive Salmonellae. 
TYPHERIX
TM
 has not been evaluated in ch